GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » ROE % Adjusted to Book Value

BriaCell Therapeutics (TSX:BCT) ROE % Adjusted to Book Value : 0.00% (As of Jan. 2024)


View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics ROE % Adjusted to Book Value?

BriaCell Therapeutics's ROE % for the quarter that ended in Jan. 2024 was 0.00%. BriaCell Therapeutics's PB Ratio for the quarter that ended in Jan. 2024 was N/A. BriaCell Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jan. 2024 was N/A.


BriaCell Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for BriaCell Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics ROE % Adjusted to Book Value Chart

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -41.03 -14.86 -

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - Negative Equity -

Competitive Comparison of BriaCell Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, BriaCell Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's ROE % Adjusted to Book Value falls into.



BriaCell Therapeutics ROE % Adjusted to Book Value Calculation

BriaCell Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Jul. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-640.73% / N/A
=N/A

BriaCell Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jan. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BriaCell Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (TSX:BCT) Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

BriaCell Therapeutics (TSX:BCT) Headlines

No Headlines